Drug intelligence / Profile preview

VCT220

Development stage: Phase 3
Lead developer: CORXEL Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

VCT220 (also known as CX11) is an oral small molecule glucagon-like peptide-1 receptor agonist (GLP-1 RA) developed for the treatment of obesity, overweight, and type 2 diabetes. It acts by stimulating the GLP-1 receptor to enhance insulin secretion and reduce appetite, leading to weight loss and improved glycemic control. Clinical trials have demonstrated significant reductions in body weight with a favorable tolerability profile and no drug-induced liver injury observed. The drug is being developed by Corxel Pharmaceuticals in collaboration with Chengdu Vincentage Pharma Co., Ltd., with ongoing Phase 3 trials for obesity in China and Phase 2 development globally[4][6][5].

Other names: CX11CX-11CX 11

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on VCT220.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VCT220.

Explore the full profile